DNA

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland

Ginkgo provides an update on its second quarter financial results and its continued efforts to scale Nebula, its Boston-based autonomous cloud lab

BOSTON, Mass – August 5, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the second quarter of 2026 that ended June 30, 2026. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.

Second Quarter 2026 Financial Results

•Second quarter 2026 Revenue of $20 million compared to $39 million in the comparable prior year period, a decrease of 48%. The decrease in revenue is primarily attributed to ongoing program rationalization as part of our restructuring activities.

•Second quarter 2026 GAAP net loss from continuing operations of ($57) million, compared to ($53) million in the comparable prior year period.

•Second quarter 2026 Adjusted EBITDA of ($36) million, down from ($25) million in the comparable prior year period.

•Cash, cash equivalents and marketable securities balance as of June 30, 2026 of $302 million.

"Autonomous labs are increasingly becoming necessary national infrastructure for American science," said Jason Kelly, Co-founder and CEO of Ginkgo Bioworks. "The White House and the National Science Foundation are now investing billions to move experimentation off the bench and into AI-enabled labs that scientists can run from anywhere, and Ginkgo is proud to be helping build that future—both with Nebula, already the world's largest autonomous lab, and by powering several of the new NSF cloud lab nodes with our automation. We're using that same infrastructure to bring high-value R&D back onshore to the U.S., and to help lead the transition from the manual lab bench to autonomous research infrastructure that runs 24/7 and plugs directly into the AI models transforming drug discovery."

Recent Business Highlights & Strategic Positioning

•Autonomous labs are becoming an imperative for American science.

◦The White House has called for the U.S. to "build autonomous laboratories that leverage robotics, edge AI, and real-time analysis to enable self-driving experimentation…which scientists can run and replicate from anywhere in the country," backed by $5 billion of investment through the Genesis Mission.

◦Caltech, Northwestern, and the University of Maryland have all commissioned autonomous labs to be built by Ginkgo under the NSF’s ~$400 million investment to establish a national network of AI-enabled "cloud labs".

◦MIT Media Lab awarded grant from the Massachusetts Life Sciences Center to build a Cloud Laboratory for Learning, supported by Ginkgo RACs.

◦Ginkgo has begun work on a $47 million, 97-instrument autonomous lab for the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory.

•Nebula, our autonomous lab, is the largest in the world—and it is scaling rapidly.

◦Nebula is in “ramp” mode, scaling rapidly as we onboard new protocols to the system weekly.

◦More than 100 robots can run experiments around the clock for our Cloud Lab, Datapoints, and Solutions businesses.

◦In Q3, we are increasing the total number of devices housed in Nebula’s RACs.

•Our pharma services continue to onshore American industry through innovation.

◦Ginkgo believes it is well positioned to provide core next-gen R&D infrastructure / services to U.S.-based biopharma companies.

◦Our new ADME-One service is cheaper than WuXi by 10X, with work done in Boston, and has signed on 17 customers in the first 6 weeks.

◦More expected soon: automated nano-scale chemistry on RACs, multistep synthesis, safety-seq, biochemical screens.

Full Year 2026 Outlook

•Ginkgo reaffirms expected total cash burn of ($150)-($125) million in 2026.

Conference Call Details

Ginkgo will host a videoconference today, Wednesday, August 5, beginning at 4:30 p.m. ET. The presentation will include an overview of the second quarter 2026, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.

Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

Audio-Only Dial Ins:

+1 646 876 9923 (New York - ET)

+1 301 715 8592 (Washington DC - ET)

+1 305 224 1968 (Miami - ET)

+1 689 278 1000 (Orlando - ET)

+1 312 626 6799 (Chicago - CT)

+1 507 473 4847 (Minnesota - CT)

+1 346 248 7799 (Houston - CT)

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business

BOSTON, Mass – May 7, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.

First Quarter 2026 Financial Results

•As previously announced, Ginkgo completed the divestiture of its Biosecurity business on April 3, 2026 and is presenting the financial results of operations for the former business within discontinued operations. Accordingly, Ginkgo’s previously reported financial results for comparable periods have been retrospectively recast to conform to this presentation and reflect Ginkgo as a single reporting segment.

•First quarter 2026 Revenue of $19 million compared to $38 million in the comparable prior year period, a decrease of 49%. As previously reported, the first quarter of 2025 benefited from $7 million of non-cash revenue from previously announced release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this non-cash deferred revenue release, first quarter 2026 Revenue of $19 million, down from $31 million in the comparable prior year period, a decrease of 37%. The decrease in revenue is primarily attributed to ongoing program rationalization as part of our restructuring activities.

•First quarter 2026 GAAP net loss from continuing operations of $(76) million, compared to $(83) million in the comparable prior year period.

•First quarter 2026 Adjusted EBITDA of $(42) million, down from $(44) million in the comparable prior year period.

•Cash, cash equivalents and marketable securities balance as of March 31, 2026 of $373 million.

"We believe autonomous labs will replace the lab bench more quickly than people think," said Jason Kelly, Co-founder and CEO of Ginkgo Bioworks. "Nebula is already the world's largest autonomous lab with the ability to run real customer science around the clock and we're targeting to double its size this year. We see a large market that remains overwhelmingly manual today, and every experiment our Solutions, Datapoints, and Cloud Lab businesses run on Nebula generates revenue today while making the platform better for tomorrow. Ginkgo is singularly focused on leading the transition from the lab bench to autonomous research infrastructure that runs 24/7 and integrates directly with the AI models transforming drug discovery and industrial biotechnology."

Recent Business Highlights & Strategic Positioning

•We believe that autonomous labs will replace the bench.

◦The return on investment of the autonomous lab is clear for customers, with millions of square feet and tens of billions per year being spent on work happening at the lab bench

◦The autonomous lab is a machine that can run 24/7 and can be seamlessly integrated into emerging AI models

•Nebula, our autonomous lab, is showing what is possible at the bleeding edge.

◦Nebula is the world’s largest autonomous lab and in 2026 we are aiming to double its size

◦Recent coverage positions Ginkgo at the frontier of scientific innovation in the scientific (Nature), trade (R&D World), mainstream (Forbes, The Washington Post), and tech press (Sequoia’s Training Data, TBPN)

◦Policymakers and heads of R&D visit for our internal demonstrations. During SLAS 2026, over 500 visitors came to tour Nebula

•Cloud Lab, Datapoints, and Solutions are our version of Starlink.

◦They both create revenue and speed the development of the autonomous lab

◦We are seeing traction with our Cloud Lab from partners such as ProQR and Amazon, who included us as an integrated wet lab partner on their Amazon Bio Discovery platform

Full Year 2026 Outlook

•Ginkgo reaffirms expected total cash burn of $(150)-$(125) million in 2026.

Conference Call Details

Ginkgo will host a videoconference today, Thursday, May 7, beginning at 4:30 p.m. ET. The presentation will include an overview of the first quarter 2026, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.

Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

Audio-Only Dial Ins:

+1 646 876 9923 (New York - ET)

+1 301 715 8592 (Washington DC - ET)

+1 305 224 1968 (Miami - ET)

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business

Ginkgo provides an update on its fourth quarter and full year financial results

BOSTON, Mass – February 26, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

Fourth Quarter 2025 Financial Results

•Fourth quarter 2025 Total revenue of $33 million compared to $44 million in the comparable prior year period, Total revenue in the fourth quarter of 2025 decreased 24% from the comparable prior year period.

◦Fourth quarter 2025 Cell Engineering revenue of $26 million compared to $35 million in the comparable prior year period, a decrease of 26%

◦Fourth quarter 2025 Biosecurity revenue of $7 million compared to $9 million in the comparable prior year period

•Fourth quarter 2025 GAAP net loss of $(81) million, compared to $(108) million in the comparable prior year period

•Fourth quarter 2025 Adjusted EBITDA of $(36) million, up from $(57) million in the comparable prior year period, primarily attributable to the decrease in operating expenses in the prior year period

•Cash, cash equivalents and marketable securities balance as of December 31, 2025 of $423 million

“This year, we are going to focus on investing to win in the category of autonomous labs,” said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. “There is an emerging wave of interest in robotics and AI, and our work with the Department of Energy and OpenAI this year shows that Ginkgo is in the best position to bring robotics to an extraordinarily high value area: laboratory research.”

Full Year 2025 Financial Results

•Full year 2025 Total revenue of $170 million, down from $227 million in the prior year, a decrease of 25% driven by the shift from early stage customers to large/enterprise customers along with commercial changes related to the restructuring. Full year 2025 and 2024 also benefited from $8 million and $45 million of non-cash revenue from previously announced releases of deferred revenue relating to the mutual terminations of customer agreements.

◦Full year 2025 Cell Engineering revenue of $133 million, down from $174 million in the prior year, a decrease of 24%. Excluding the non-cash deferred revenue releases discussed above, full year 2025 and 2024 Cell Engineering revenue of $125 million and $129 million, respectively, with 2025 Cell Engineering revenue decreasing 3%, primarily attributed to ongoing program rationalization as part of our restructuring activities. Full year 2025 Biosecurity revenue of $37 million, down from $53 million in the prior year, a decrease of 30%, with full year 2025 Biosecurity gross profit margin of 23%

•Full year 2025 GAAP net loss of $(313) million, compared to $(547) million in the prior year

•Full year 2025 Adjusted EBITDA of $(167) million, improved from $(293) million in the prior year

Biosecurity Business Divestiture

Ginkgo today announced it has reached an agreement to sell the Company’s biosecurity business to a consortium of investors (“Investors”) in exchange for a minority equity position in the business alongside the Investors. Upon completion, the biosecurity business will operate as a standalone private entity focused on building a scaled, biosecurity infrastructure

platform for the United States and its global partners. The transaction provides the biosecurity business with greater flexibility and additional resources to pursue near- and long-term growth opportunities.

Per Ginkgo CEO Jason Kelly, “There is rising interest in defense tech in private capital markets and spinning off our biosecurity business into a private entity with new investors allows it to grow faster with more investment than it would inside Ginkgo. This serves Ginkgo in two ways: we are able to participate in the upside of the new entity as a shareholder but importantly we also focus Ginkgo’s cash investment on our autonomous labs business.”

Ginkgo expects to complete the transaction in the first half of 2026, subject to the satisfaction of customary closing

conditions.

Recent Business Highlights & Strategic Positioning

•We are making 2026 a year of investment in our autonomous lab.

◦This year, we will focus Ginkgo's efforts on autonomous labs as the common platform for biotechnology research and invest to extend our current lead in technology. We are currently expanding our frontier autonomous lab in Boston to include over 50 RACs, with 50 more expected by the end of the year

◦We will demonstrate the capabilities of autonomous labs by decommissioning the majority of Ginkgo's

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports Third Quarter 2025 Financial Results

Ginkgo provides an update on its third quarter financial results

BOSTON, Mass – November 6, 2025 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the third quarter ended September 30, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

Third Quarter 2025 Financial Results

•Third quarter 2025 Total revenue of $39 million compared to $89 million in the comparable prior year period, a decrease of 56%, which prior year included $45 million of non-cash revenue from a release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this prior year impact, Total revenue in the third quarter of 2025 decreased 11% from the comparable prior year period.

◦Third quarter 2025 Cell Engineering revenue of $29 million compared to $75 million in the comparable prior year period, a decrease of 61%, which prior year included the above noted $45 million of non-cash revenue. Excluding this prior year impact, Cell Engineering revenue in the third quarter of 2025 decreased slightly from the comparable prior year period.

◦Third quarter 2025 Biosecurity revenue of $9 million compared to $14 million in the comparable prior year period

•Third quarter 2025 GAAP net loss of $(81) million, compared to $(56) million in the comparable prior year period, primarily attributable to the above noted non-cash deferred revenue release in the prior year period

•Third quarter 2025 Adjusted EBITDA of $(56) million, down from $(20) million in the comparable prior year period, primarily attributable to the above noted non-cash deferred revenue release in the prior year period

•Cash, cash equivalents and marketable securities balance as of September 30, 2025 of $462 million

"Our recent partnership announcements are powerful examples of how Ginkgo’s AI-enabled cloud lab technology can be deployed to accelerate U.S. scientific innovation,” said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. “The recent AI Action Plan from President Trump specifically called for investment in AI-enabled cloud laboratories to keep the American bioeconomy competitive. Ginkgo’s tools are designed to generate the massive, high-quality datasets that modern AI methods need, furthering the goal of the U.S. remaining at the forefront of the bioeconomy."

Recent Business Highlights & Strategic Positioning

•We believe AI models will impact biotechnology in two ways and Ginkgo is well-positioned to provide tools in both

◦First, we see reasoning models controlling lab automation. Since science moves forward on the back of lab data and reasoning models are already capable of planning and analyzing experiments, we believe coupling reasoning models to automation will allow science to move as fast as human ideas.

◦Second, we see AI models that predict and generate new biological discoveries. Protein models such as AlphaFold prove the potential of large AI models. These models require the type of large training sets of biological data that Ginkgo provides.

•We continue to offer research solutions on top of our in-house robotics, winning us new deals in Agriculture and with the U.S. Government

◦We announced the extension of our multi-year strategic partnership with Bayer to continue advancing the research and development of biological products for agriculture. The collaboration, which began in 2017, will build on the success of developing an innovative nitrogen fixation platform, and Bayer continues to be a major partner for Ginkgo’s expanded agricultural biologicals R&D platform.

◦We were recently awarded a project agreement through the Biomedical Advanced Research and Development Authority’s (BARDA) BioMaP-Consortium with a total contract value of up to $22.2 million to develop innovations in monoclonal antibody biomanufacturing and to produce an anti-filovirus medical countermeasure

•We are expanding our frontier autonomous lab in Boston as a showcase. Please visit!

◦We'll soon have 46 major instruments on 36 Reconfigurable Automation Carts (RACs). With these RACS, we can apply AI reasoning models and “lab in the loop” to your scientific challenges. Upon successful proof-of-concept, we can build and install a system so you can run it at your own site.

◦We can have your workflows running on the system in a matter of weeks if we have the required equipment. Reach out for a demo!

Full Year 2025 Outlook

•Ginkgo reaffirms Total revenue of $167-$187 million in 2025

◦Ginkgo continues to expect Cell Engineering revenue of $117-$137 million in 2025

◦Ginkgo continues to expect Biosecurity revenue of at least $40 million in 2025

Conference Call Details

Ginkgo will host a videoconference today, Thursday, November 6, 2025, beginning

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets

BOSTON, Mass – August 7, 2025 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

Second Quarter 2025 Financial Results

•Second quarter 2025 Total revenue of $50 million, down from $56 million in the comparable prior year period

◦Second quarter 2025 Cell Engineering revenue of $39 million, up from $36 million in the comparable prior year period, an increase of 8%, primarily driven by growth with biopharma and government customers

◦Second quarter 2025 Biosecurity revenue of $10 million, down from $20 million in the comparable prior year period

•Second quarter 2025 GAAP net loss of $(60) million, compared to $(217) million in the comparable prior year period

•Second quarter 2025 Adjusted EBITDA of $(28) million, up from $(99) million in the comparable prior year period, driven by a decrease in operating expenses

•Cash, cash equivalents and marketable securities balance as of June 30, 2025 of $474 million

“Our platform is proving to be a critical engine for AI in biology, with growing demand for our automation and data generation capabilities,” said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. “This is translating into commercial traction, including major new government contracts and expanded service offerings in response to demand in the biopharma industry. This progress is backed by rigorous financial discipline, allowing us to achieve our $250 million annualized cost-reduction goal three months ahead of schedule.”

Recent Business Highlights & Strategic Positioning

•Ginkgo’s Automation and Datapoints offerings continue to establish themselves as critical tools in AI-powered bioengineering

◦Pacific Northwest National Laboratory (PNNL) selected Ginkgo Automation to deliver a state-of-the-art automated anaerobic phenotyping platform, to assist with what is believed to be the largest automated anaerobic system for research in the world

◦Ginkgo launched a new in vitro ADME profiling Service, built on its proprietary RAC automation system. Designed for scale and efficiency, the Service delivers assay quality at cost-effective pricing and includes a price-matching guarantee. By automating traditionally labor-intensive assays and executing them onshore, Ginkgo enables customers to profile more compounds earlier, accelerate decision-making, train AI/ML models, and reduce costs while protecting valuable IP. This launch strengthens Ginkgo’s position as a differentiated US-based partner in preclinical R&D analytical services for small molecule drug development.

•Ginkgo launched its first direct-to-scientist product: a cell-free protein synthesis system

◦This E. coli-based system is optimized for high production from linear DNA, increased solubility of difficult-to-express proteins, and compatibility with automation

•Ginkgo continues to progress towards its objective to reach Adjusted EBITDA breakeven by the end of 2026

◦Ginkgo has achieved its target to reach $250 million in annualized cost reduction three months ahead of schedule, through reductions in force and other cost cutting measures. Site consolidation efforts were substantially completed by the year ended 2024, with excess space available for sublease.

Full Year 2025 Outlook

•Ginkgo reaffirms Total revenue of $167-$187 million in 2025

◦Ginkgo continues to expect Cell Engineering revenue of $117-$137 million in 2025

◦Ginkgo expects Biosecurity revenue of at least $40 million in 2025

Conference Call Details

Ginkgo will host a videoconference today, Thursday, August 7, 2025, beginning at 5:30 p.m. ET. The presentation will include an overview of the second quarter of 2025, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.

Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

Audio-Only Dial Ins:

+1 646 876 9923 (New York)

+1 301 715 8592 (Washington DC)

+1 305 224 1968 (Miami)

+1 312 626 6799 (Chicago)

+1 346 248 7799 (Houston)

+1 408 638 0968 (San Jose)

+1 564 217 2000 (Seattle)

+1 689 278 1000 (Orlando)

Webinar ID: 953 3421 4604

If you experience technical diffic

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports First Quarter 2025 Financial Results

Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target

Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems

BOSTON, Mass – May 6, 2025 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

First Quarter 2025 Financial Results

•First quarter 2025 Total revenue of $48 million, up from $38 million in the comparable prior year period, an increase of 27% primarily due to $7 million of non-cash revenue from the release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this impact, Total revenue in the quarter was $41 million, an increase of 8% over the prior year period.

◦Excluding the $7 million non-cash deferred revenue release, first quarter 2025 Cell Engineering revenue of $31 million, up from $28 million in the comparable prior year period, an increase of 10%, primarily driven by growth with biopharma and government customers

◦First quarter 2025 Biosecurity revenue of $10 million, flat to $10 million in the comparable prior year period

•First quarter 2025 GAAP net loss of $(91) million, compared to $(166) million in the comparable prior year period

•First quarter 2025 Adjusted EBITDA of $(47) million, up from $(117) million in the comparable prior year period, driven by the increase in revenue as well as a decrease in operating expenses

•Cash, cash equivalents and marketable securities balance as of March 31, 2025 of $517 million

“We're starting the year on a solid base thanks to the significant restructuring efforts of the past year,” said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. “Our Solutions business has become a trusted R&D service provider to the US Government and biopharma industry, meanwhile our Tools businesses have traction with existing offerings and are positioned to meet emergent opportunities in areas like AI, which are driving demand for large scale biological datasets. Through all of this, we are maintaining our commitment to achieving our cost reduction targets.”

Recent Business Highlights & Strategic Positioning

•Biotechnology remains a critical emerging technology area in the US and Ginkgo is well positioned to provide biosecurity and R&D services

◦Office of Science and Technology Policy (OSTP) Director Michael Kratsios and the National Security Commission on Emerging Biotechnology (NSCEB) report have both recently emphasized biotech as an area of national importance

◦We have 28 US Government projects across Cell Engineering and Biosecurity with ~$180M of contracted backlog and unfunded potential backlog

•Ginkgo’s Datapoints and Automation offerings are seeing new deals and opportunities emerging

◦Datapoints published GDPa1, an antibody developability dataset for 246 IgGs across 10 assays, generated using Ginkgo's high-throughput PROPHET-Ab platform

◦Automation signed a deal recently with Aura Genetics, our first diagnostics company customer

•We made progress on our objective to reach Adjusted EBITDA breakeven by the end of 2026

◦Ginkgo’s reduction in force and other cost cutting measures have achieved an annualized run-rate cost reduction of $205 million as of the first quarter of 2025, with a target to achieve $250 million in cost reduction by the end of the third quarter of 2025. Site consolidation efforts were substantially completed by the year ended 2024, with excess space available for sublease.

Full Year 2025 Guidance

•Ginkgo previously issued 2025 guidance for Total revenue of $160-$180 million, Cell Engineering revenue of $110-$130 million; and Biosecurity revenue of at least $50 million. Ginkgo updates its previously issued guidance solely to reflect the impact of the previously mentioned $7 million non-cash deferred revenue release in the first quarter to:

◦Total revenue of $167-$187 million in 2025;

◦Cell engineering revenue of $117-$137 million in 2025; and

◦Biosecurity revenue of at least $50 million in 2025.

Conference Call Details

Ginkgo will host a videoconference today, Tuesday, May 6, 2025, beginning at 5:30 p.m. ET. The presentation will include an overview of the first quarter of 2025, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobiowo

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target

Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023

BOSTON, Mass – February 25, 2025 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

Fourth Quarter 2024 Financial Results

•Fourth quarter 2024 Total revenue of $44 million, up from $35 million in the comparable prior year period

◦Fourth quarter 2024 Cell Engineering revenue of $35 million, up from $27 million in the comparable prior year period, an increase of 29% driven by growth with large biopharma customers

◦Fourth quarter 2024 Biosecurity revenue of $9 million, up from $8 million in the comparable prior year period, with gross profit margin of 17%

•Fourth quarter 2024 GAAP net loss of $(108) million, compared to $(212) million in the comparable prior year period

•Fourth quarter 2024 Adjusted EBITDA of $(57) million, up from $(101) million in the comparable prior year period, driven by the increase in revenue as well as a decrease in operating expenses

•Cash and cash equivalents balance as of December 31, 2024 of $562 million. Cash flow of $(55) million in the fourth quarter of 2024, up from $(114) million in the third quarter of 2024.

"I’m very proud of the team for pushing the technical envelope and delivering for our customers as we enter this new year," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "We made a lot of changes in 2024, but our commitment to our mission is as strong as ever. Our expansions into life science tools with our Datapoints and Automation offerings are going well and we are continuing to drive our cost-cutting and sustainable revenue-generating efforts as we enter a very exciting year for Ginkgo."

Full Year 2024 Financial Highlights

•Full year 2024 Total revenue of $227 million, down from $251 million in the prior year, a decrease of 10% as Biosecurity revenue transitioned from K-12 testing to a more recurring business model. Full year 2024 also benefited from $45 million of non-cash revenue from a release of deferred revenue in the third quarter relating to the mutual termination of a customer agreement.

◦Full year 2024 Cell Engineering revenue of $174 million, up from $144 million in the prior year, an increase of 21%. Excluding the $45 million non-cash deferred revenue release in the third quarter, full year 2024 Cell Engineering revenue of $129 million decreased 10%, driven by the shift from early stage customers to large/enterprise customers along with commercial changes related to the restructuring.

◦Full year 2024 Biosecurity revenue of $53 million, down from $108 million in the prior year, a decrease of 51%, with full year 2024 Biosecurity gross profit margin of 27%

•Full year 2024 GAAP net loss of $(547) million, compared to $(893) million in the prior year

•Full year 2024 Adjusted EBITDA of $(293) million, up from $(365) million in the prior year

Recent Business Highlights & Strategic Positioning

•Cell Engineering closed deals with new and existing customers

◦Added 31 new programs and other customer contracts to the Cell Engineering platform in Q4 2024, of which 14 were comparable in size and scope to historically reported New Programs, and an additional 17 contracts that represent a variety of other deal archetypes, such as Datapoints projects

◦Signed contract for our Antibody Developability product from Ginkgo Datapoints with a top biopharma company

◦Ginkgo Automation was selected to deploy a flexible laboratory automation system for cutting-edge biofuels and bioproducts research at Great Lakes Bioenergy Research Center (“GLBRC”), and demonstrated its technology at the 2025 annual meeting of the Society for Laboratory Automation and Screening (“SLAS”)

◦Awarded up to $9.4 million in partnership with Carnegie Mellon University to develop implantable cell-based bioelectronic devices for disease treatment under ARPA-H's REACT program

•Ginkgo Biosecurity continues to work towards creating solutions that offer persistent, pervasive monitoring of biothreats

◦Awarded contract with the European Health and Digital Executive Agency (“HaDEA”) to deliver next-generation ‘agnostic diagnostics’ for respiratory viruses at the point of care, with Ginkgo and its consortium partners eligible to receive up to €24 million over the next 4 years

•Ginkgo ma

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions

Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck

BOSTON, Mass – November 12, 2024 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com.

Third Quarter 2024 Financial Results

•Third quarter 2024 Total revenue of $89 million, up from $55 million in the comparable prior year period, an increase of 61% driven by $45 million of non-cash revenue from a release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this impact, Total revenue in the quarter was $44 million, a decrease of 21% over the prior year period

◦Excluding the $45 million non-cash deferred revenue release, third quarter 2024 Cell Engineering revenue of $30 million, down from $37 million in the comparable prior year period, a decrease of 20% driven by the continued shift from early stage customers to large/enterprise customers along with commercial changes related to the restructuring

◦Third quarter 2024 Biosecurity revenue of $14 million with gross profit margin of 28%. Biosecurity revenue decreased from the comparable prior year period due to the expected ramp down of K-12 testing

•Third quarter 2024 Loss from operations of $(55) million (inclusive of stock-based compensation expense of $14 million and M&A and restructuring related costs of $2 million, net), compared to Loss from operations of $(286) million (inclusive of stock-based compensation expense of $54 million and M&A and restructuring related costs, including asset impairments, of $124 million) in the comparable prior year period. The 2024 period also benefited from the above non-cash deferred revenue release

•Third quarter 2024 Adjusted EBITDA of $(20) million, up from $(84) million in the comparable prior year period, driven by the above non-cash deferred revenue release and a decrease in operating expenses

•Cash and cash equivalents balance as of the end of the third quarter of $616 million

“I’m extremely proud of the significant progress we made in the third quarter,” said Jason Kelly, co-founder and CEO of Ginkgo. “The team has been laser-focused on delivering for customers while driving down costs even further. We are achieving ambitious milestones, signing new deals with several new and existing customers while also launching our new Automation, Datapoints and AI offerings. Beyond customer successes, we will substantially consolidate our overall real estate footprint by exiting several facilities in Cambridge, MA and Europe by year end. We couldn’t have done this without the support of our Board and we’re very grateful to Arie for all of his service and contributions to our journey since going public, and look forward to working closely with Sri as he brings a wealth of knowledge in the automation and life science tools space as we expand increasingly into tools. It’s an incredibly important time to be pursuing the mission of making biology easier to engineer and creating sustainable biosecurity infrastructure for the future. I am excited by the momentum we are gaining to meet that mission as we close out this year on a substantially reduced cost base.”

Recent Business Highlights & Strategic Positioning

•Cell Engineering closed deals with new and existing customers

◦Added 25 new programs and other customer contracts to the Cell Engineering platform in Q3 2024, of which 11 were comparable in size and scope to historically reported New Programs and an additional 14 contracts that represent a variety of other deal archetypes, such as Datapoints projects

◦Signed a new deal with Novo Nordisk focused on the discovery and development of proteins while also expanding Ginkgo’s existing collaboration on expression systems for pharmaceutical products

◦Delivered on a major research milestone for Ginkgo’s previously announced deal with Merck. As part of this milestone completion, Ginkgo will receive a fee of $9 million in cash, expected in Q4 2024, and will move to Stage 2 to work towards making an even more effective production process

◦Signed three new Datapoints deals with a major TechBio company and two of the top 25 pharmaceutical companies

•Ginkgo Biosecurity continues to work towards creating solutions that offer persistent, pervasive monitoring

◦Ginkgo validated its approach to rapidly detect H5N1 and has updated its offerings to include DNA sequencing of raw milk,

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports Second Quarter 2024 Financial Results

Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force

BOSTON, Mass – August 8, 2024 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2024. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Second Quarter 2024 Financial Results

•Second quarter 2024 Total revenue of $56 million, down from $81 million in the comparable prior year period, a decrease of 30% primarily driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity segment

◦Second quarter 2024 Cell Engineering revenue of $36 million, down from $45 million in the comparable prior year period, a decrease of 20% driven by a decline in revenue from early stage customers partially offset by growth from large/enterprise customers

◦Second quarter 2024 Biosecurity revenue of $20 million with gross profit margin of 41%

•Second quarter 2024 Loss from operations of $(223) million (inclusive of stock-based compensation expense of $38 million and M&A and restructuring related costs, including asset impairments, of $72 million), compared to Loss from operations of $(184) million (inclusive of stock-based compensation expense of $62 million and M&A and restructuring related costs, including asset impairments, of $26 million) in the comparable prior year period

•Second quarter 2024 Adjusted EBITDA of $(99) million, down from $(80) million in the comparable prior year period, driven by the decrease in Total revenue partially offset by a decrease in certain operating expenses

•Cash and cash equivalents balance as of the end of the second quarter of $730 million

“This past quarter was a quarter of focused execution for Ginkgo,” said Jason Kelly, co-founder and CEO of Ginkgo. “During the Q1 2024 earnings call, we announced that we were taking decisive action to reduce costs in order to reach Adjusted EBITDA breakeven by the end of 2026 and, in June, we commenced a reduction in force impacting 35% of the workforce. Alongside the RIF, we continued to deliver well for customers as reflected in our second quarter revenue and I’m happy we have gained initial traction with our new lab data as a service (“LDaaS”) offering, including our first few deals with a large cap tech company.”

Recent Business Highlights & Strategic Positioning

•Cell Engineering worked to close deals as Ginkgo’s new commercial terms begin to gain traction

◦Added 18 new programs and other customer contracts to the Cell Engineering platform in Q2 2024, of which 10 were comparable in size and scope to historically reported New Programs and an additional 8 contracts that represent a variety of smaller deal archetypes, such as LDaaS projects

◦Signed first LDaaS deals with a large cap tech company in protein characterization

◦Delivered on a major technical milestone for a large pharmaceutical customer

◦Announced a new collaboration with Syngenta Crop Protection aimed at accelerating the launch of a new biological solution to develop and optimize a microbial strain that can

meet the productivity targets of a secondary metabolite from the Syngenta Biologicals pipeline

•Ginkgo Biosecurity continues to work towards creating solutions that offer persistent, pervasive monitoring

◦Ginkgo has put forth a proposed Genomic Analysis Program to address the threat of H5N1. The program builds upon existing practices of pooling and sampling milk for food safety, and integrates novel capabilities to generate genomic analysis of H5N1 if it spreads and evolves

•Ginkgo began executing on its plan to reach Adjusted EBITDA breakeven by the end of 2026

◦The reduction in force is estimated to achieve over $85 million in annualized savings by mid-2025

◦Ginkgo is also implementing significant non-people cost cutting measures, including rationalizing third-party costs and site consolidation

Full Year 2024 Outlook

•Ginkgo reaffirms Total revenue of $170-$190 million in 2024

◦Ginkgo continues to expect Cell Engineering services revenue of $120-140 million in 2024

◦Ginkgo continues to expect Biosecurity revenue of at least $50 million in 2024

Conference Call Details

Ginkgo will host a videoconference today, Thursday, August 8, 2024, beginning at 5:30 p.m. ET. The presentation will include an overview of second quarter financial performance, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobiow

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports First Quarter 2024 Financial Results

Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026

Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025, with anticipated substantial reduction occurring in 2024

BOSTON, Mass – May 9, 2024 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2024. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

First Quarter 2024 Financial Results

•First quarter 2024 Total revenue of $38 million, down from $81 million in the comparable prior year period, a decrease of 53% primarily driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity segment

◦First quarter 2024 Cell Engineering revenue of $28 million, down from $34 million in the comparable prior year period, a decrease of 18% driven by a decline in revenue from early stage customers partially offset by growth from large/enterprise customers

◦First quarter 2024 Biosecurity revenue of $10 million with gross profit margin of 8% is reflective of the early stages of transition to a more recurring business model

•First quarter 2024 Loss from operations of $(178) million (inclusive of stock-based compensation expense of $42 million), compared to Loss from operations of $(216) million (inclusive of stock-based compensation expense of $75 million) in the comparable prior year period

•First quarter 2024 Adjusted EBITDA of $(100) million remained flat year over year as the decrease in Total revenue was offset by a decrease in operating expenses

•Cash and cash equivalents balance as of the end of the first quarter of $840 million

“Ginkgo is an increasingly important part of the biotech ecosystem, and we are taking decisive action to keep it that way,” said Jason Kelly, co-founder and CEO of Ginkgo. “We’ve demonstrated that we can serve a large number of diverse programs on a common platform, but I’m disappointed in our revenues in Q1. This trend needs to change, and we are simplifying both what we sell to customers and how we do the work that drives revenue at Ginkgo. Fortunately, we have the experience to know which types of programs are most efficient to run on our lab automation and can use this knowledge to further consolidate our Foundry operations and footprint into Biofab1, our new fully integrated lab data center, which is expected to open in mid-2025. We are also simplifying our transaction terms in many instances as the benefits of our IP and downstream value terms were not worth the cost of slowing our commercial activity. With these changes, we are targeting reaching adjusted EBITDA breakeven by the end of 2026, while seeking to reduce interim burn substantially to maintain a strong margin of safety throughout this transformation, supported by our $840 million cash balance and no bank debt.”

Recent Business Highlights & Strategic Positioning

•Cell Engineering business seeing opportunities to simplify operations, with a focus on more profitable and scalable programs

◦Added 17 new Cell Programs to the Foundry platform in Q1 2024, representing 31% growth over the prior year period

◦Expanded partnership with Novo Nordisk, creating a flexible model to allow projects to launch more quickly across several areas of interest in their portfolio

◦Introduced Lab Data as a Service (“LDaaS”) offering to meet market demand for high quality training data for AI (“lab in the loop”) and more modular R&D workflows

•Ginkgo Biosecurity continues to gain traction on an international scale

◦Awarded a grant from the Bill & Melinda Gates Foundation to build an open-access, AI-enabled forecasting model for global measles outbreaks to empower proactive public health measures

◦Announced Ginkgo’s new biosecurity products, Ginkgo Canopy and Ginkgo Horizon. Ginkgo Canopy is our end-to-end system to monitor key nodes across the world for biothreats while Ginkgo Horizon enables global situational awareness and informs critical decisions through AI-powered multi-source data integration, analysis, and forecasting. With these products, Ginkgo is allowing customers to access biosecurity data feeds on a subscription basis and is building a true common operating picture for biothreats.

Plan to Achieve Adjusted EBITDA Breakeven and Updated Full Year 2024 Guidance

•Ginkgo announced a plan to achieve Adjusted EBITDA break-even by the end of 2026 on an annualized run-rate basis. The plan includes the following:

◦A target reduction in annualized run-rate operating expenditures of $200 million by mid-2025, driven by:

▪Consolidation of Foundry operations into a small number o

EX-99.1

2 ex-991fy2023earnings.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results

$251 million of Total revenue in 2023

$139 million in Cell Engineering services revenue, representing 31% growth over 2022

78 new Cell Programs added in 2023, representing 32% growth over 2022 and continued penetration in biopharma

Year-end cash balance of nearly $950 million provides meaningful multi-year runway as we drive towards profitability and begin recognizing benefits from improved platform efficiency

BOSTON, Mass – February 29, 2024 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2023. The update, including a webcast slide presentation and supplemental financial information, will be available at investors.ginkgobioworks.com.

“2023 was a breakout year for Ginkgo,” said Jason Kelly, co-founder and CEO of Ginkgo. “We’re working to build a durable platform that fundamentally transforms R&D in biotech. I’m particularly pleased with our growth in biopharma, which represents our largest untapped market - we added several new programs across modalities with large enterprises including Boehringer Ingelheim, Merck, Novo Nordisk, and Pfizer and are seeing strong momentum in pharma going into 2024. I am also thrilled to see a real ecosystem building around Ginkgo - we’re honored by the trust placed in us by the terrific founders of Patch Biosciences, Reverie Labs, and Proof Diagnostics to bring their technologies to customers and by the over 25 inaugural partners in our newly announced Technology Network. We are committed to bringing the best technologies together to support our customers, and we’ve never been better positioned to deliver.”

Recent Business Highlights & Strategic Positioning

•Added 78 new Cell Engineering Programs in 2023, representing 32% growth over the prior year period

•Ginkgo’s Cell Engineering segment generated services revenue, which does not include downstream value share revenue, of $139 million in 2023, a 31% increase versus 2022

•Ginkgo’s Biosecurity segment generated $108 million of revenue in 2023 as the Biosecurity business shifted to a more recurring model focused on global reach and multiple pathogens to build a long-term biosecurity global infrastructure

◦Ginkgo continues to expand its global bioradar network—now in 14 countries and 10 airports—and advance capabilities for multi-target and multimodal biological threat detection, characterization, and forecasting for next-generation biological intelligence

◦Ginkgo is partnering with the Qatar Free Zones Authority (QFZ) and Doha Venture Capital (DVC) to build a Center for Unified Biosecurity Excellence in Doha (CUBE-D), envisioned as the first of several hubs for biosecurity sample and data analysis in our global network

◦Ginkgo is partnering with Illumina, a global leader in DNA sequencing and array-based technologies, to advance localized biosecurity capabilities in countries around the world

•Downstream value share – which consists of potential value to Ginkgo from its Cell Engineering customers and includes potential royalties, milestone payments, and equity interests – is an important component of the financial potential of most programs. As of December 31, 2023 Ginkgo has approximately $2.4 billion in aggregate revenue potential from downstream milestone payments alone in addition to royalties.

•Ginkgo recently announced the launch of its Technology Network of over 25 companies, creating a more integrated approach to biotech R&D. Ginkgo has a long history of integrating diverse technologies to deliver on customers’ complex program goals and believes that customers should not have to choose a technical approach prematurely but should be able to test many approaches in an unbiased way. Ginkgo customers will be able to benefit from the integration of technologies from network partners in their programs, and Ginkgo expects to expand the network based on customer needs and feedback.

•Ginkgo also announced several acquisitions including Patch Biosciences, Proof Diagnostics and Reverie Labs. These acquisitions are expected to expand Ginkgo’s capabilities in AI and biopharma.

Fourth Quarter 2023 Financial Highlights

•Fourth quarter 2023 Total revenue of $35 million, down from $98 million in the comparable prior year period, a decrease of 65% primarily driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity segment and the impact of Cell Engineering downstream value share from equity milestones in 2022 that did not recur in 2023

◦Fourth quarter 2023 Cell Engineering services revenue, which does not include downstream value share revenue, of $27 million, down 26% from $36 million in the comparable prior year period. There was no material downstream value share revenue received in the fourth qu

EX-99.1

2 ex-991jpm11024.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference

Expects to meet 2023 new program and revenue guidance ranges

Ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as Ginkgo sees operational efficiencies in the business

Strong growth among blue chip pharma and biotech (“biopharma”) customers including Pfizer, Novo Nordisk, Merck and Boehringer Ingelheim

Management to highlight updates today at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT (12:45 p.m. ET)

BOSTON, MA – Jan. 10, 2024 – Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced preliminary performance updates for the year ended December 31, 2023. Among the results, Ginkgo highlighted that it expects to meet its previously disclosed new program and revenue guidance ranges in 2023 based on its preliminary unaudited estimates. A business review, including a discussion of Ginkgo's platform services for large scale data generation and AI to enable biopharma R&D, will be featured in a presentation today at the 42nd Annual J.P. Morgan Healthcare Conference.

"I'm very pleased with the robust revenue and program growth we have seen in 2023, particularly in the biopharma sector – growing the portion of our cell engineering revenue that is attributable to biopharma customers by more than 50% over the past year," said Jason Kelly, Ginkgo's co-founder and Chief Executive Officer. "Our strong balance sheet, with nearly $950 million of cash and cash equivalents, positions us well to take advantage of strategic opportunities while the market faces continued pressure. This, combined with the meaningful improvements we have seen in operational efficiency, gives us a long runway as we plan to increase new programs while reducing operating expenses. I'm proud of our team's accomplishments in 2023 and am excited to drive continued strong growth in our biopharma vertical in 2024."

Preliminary 2023 Key Performance Highlights

•Ginkgo continues to expect Total revenue of $250 – $260 million in 2023

◦Preliminary unaudited Cell Engineering revenue is expected to be within the previously disclosed guidance range of $145 – $150 million in 2023

◦Preliminary unaudited Biosecurity revenue is expected to be in line with the previously disclosed guidance of up to $110 million in 2023

•New Cell Programs are expected to be within the previously disclosed guidance range of 80-85 new Cell Programs added to the platform in 2023

•Ginkgo signed or advanced several major new biopharma programs in 2023, including with Pfizer, Merck, Novo Nordisk, and Boehringer Ingelheim in which Ginkgo is eligible to receive, in aggregate, over $1.2 billion in upfront research payments, research fees and development and commercial milestones. Ginkgo also successfully completed the pilot phase of a program with Novo Nordisk, as well as completed a gene therapy collaboration with Biogen.

•In connection with its strategic partnership with Google Cloud, Ginkgo is training a series of foundation and application-specific models incorporating Ginkgo’s proprietary metagenomics and assay-labeled training data as well as data from public repositories. Ginkgo’s ability to bring together automated data generation at scale with AI models targeted towards customer program areas is expected to be the foundation for additional pharmaceutical partnerships in 2024.

•Ginkgo ended 2023 with nearly $950 million of cash and cash equivalents, putting Ginkgo in a strong financial position to pursue its strategic objectives while driving towards profitability

Ginkgo plans to report fourth quarter and full year 2023 financial results in February 2024, at which time it intends to provide its outlook for full year 2024.

J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024

As previously announced, co-founder and CEO Jason Kelly is scheduled to participate in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT (12:45 p.m. ET).

Further details, a webcast link, and a replay of the presentation will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read o

EX-99.1

2 ex-991q32023earnings.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports Third Quarter 2023 Financial Results

Ginkgo added 21 new Cell Programs to the Foundry platform in Q3 2023

Entered into strategic cloud and AI partnership with Google Cloud; first milestone recently achieved

Signed new multi-target RNA drug discovery collaboration with Pfizer in which Ginkgo is eligible to receive research fees and development and commercial milestone payments of up to $331 million

Ginkgo ended Q3 2023 with over $1.0 billion in cash and cash equivalents, maintaining a multi-year runway as Ginkgo continues to drive towards profitability

BOSTON, Mass – November 8, 2023 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2023. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

“We have continued to expand our customer base and partnerships this quarter,” said Jason Kelly, co-founder and CEO of Ginkgo. “We’re particularly excited about our new program with Pfizer to advance the discovery and development of novel RNA molecules. I’m also thrilled about the five-year strategic cloud and AI partnership we signed with Google Cloud to deploy and develop AI tools for biology and biosecurity. Our team is hard at work building new, state-of-the-art foundation models that speak the languages of biology, and I couldn’t be more excited about the opportunities that lie ahead.”

Recent Business Highlights & Strategic Positioning

•Added 21 new Cell Programs to the Foundry platform in Q3 2023, representing 40% growth over the prior year period

◦Includes a multi-target RNA drug discovery collaboration with Pfizer, in which Ginkgo is eligible to receive fees and milestones up to $331 million in addition to potential royalties on sales

•Entered a strategic five-year cloud and AI partnership with Google Cloud to pioneer new large language models for biological engineering applications

•Hosted Ginkgo’s first in-person investor day, which was also streamed live online, to highlight key business updates in Cell Engineering, Biosecurity and AI

•Ginkgo’s Cell Engineering segment generated services revenue, which does not include downstream value share revenue, of $36 million, a 52% increase versus the third quarter of 2022

•Ginkgo’s Biosecurity segment generated $18 million of revenue in the third quarter as Biosecurity revenue shifted away from COVID-19 testing programs in schools and communities towards a more recurring model focused on long-term biosecurity infrastructure

◦Concentric continues to expand its global bioradar network, with partnerships in 14 countries and 9 operational airport programs

◦Concentric is maturing its bioradar offering by expanding its partnership with CDC on air travel-based pathogen monitoring to more than 30 additional priority pathogens and launching new efforts in zoonotic disease monitoring, in the U.S. and internationally

◦Concentric is building a suite of next-generation biological intelligence capabilities, including AI-based epidemic forecasting

Third Quarter 2023 Financial Highlights

•Third quarter 2023 Total revenue of $55 million, down from $66 million in the comparable prior year period, a decrease of 17% primarily driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity segment

•Third quarter 2023 Cell Engineering revenue of $37 million, up from $25 million in the comparable prior year period, an increase of 51%

•Third quarter 2023 Biosecurity revenue of $18 million with gross profit margin of 62%

•Third quarter 2023 Loss from operations of $(286) million (inclusive of stock-based compensation expense of $54 million and a non-cash impairment charge of $96 million relating to the exit of a Zymergen lease facility), compared to Loss from operations of $(655) million in the comparable prior year period (inclusive of stock-based compensation expense of $563 million). About half of the stock-based compensation expense relates to the continued GAAP accounting for the modification of restricted stock units issued prior to Ginkgo becoming a public company, as disclosed in our annual report on Form 10-K filed with the SEC on March 13, 2023, and which we expect will continue to ramp down significantly in the coming quarters

•Third quarter 2023 Adjusted EBITDA of $(84) million, down from $(72) million in the comparable prior year period driven by both the higher run-rate of expenses in Cell Engineering and the as-expected decline in Biosecurity revenue

•Cash and cash equivalents balance as of the end of the third quarter of over $1.0 billion puts Ginkgo in a strong financial position to pursue its strategic objectives

Full Year 2023 Outlook

•While Ginkgo continues to see stro

EX-99.1

2 dna-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Ginkgo Bioworks Reports Second Quarter 2023 Financial Results

Ginkgo added 21 new Cell Programs to the Foundry platform in Q2 2023

Highlighted continued success selling into large established biotech R&D organizations with recently expanded relationships with Sumitomo, Novo Nordisk, and Merck

Ginkgo ended Q2 2023 with approximately $1.1 billion in cash and cash equivalents, providing a strong multi-year runway as Ginkgo continues to drive towards profitability

BOSTON, MA – August 9, 2023 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2023. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

“I’m really energized by the work that we have done at Ginkgo this past quarter,” said Jason Kelly, co-founder and CEO of Ginkgo. “This has been a record quarter on several dimensions, we launched more programs than we ever have before and are seeing strong output from our Foundry. While we still have much more to do, many of the investments we have made to make biology more like an engineering discipline are paying off. This is being reflected not only in our output but also in the outcomes we’re delivering for our partners, and we’re honored to have more and more technically sophisticated customers trusting Ginkgo to manage their R&D efforts.”

Recent Business Highlights & Strategic Positioning

• Added 21 new Cell Programs to the Foundry platform in Q2 2023, representing 62% growth over the prior year period

o In addition to bringing new customers onto the platform, Ginkgo progressed and/or expanded several partnerships with market leading companies including Sumitomo, Novo Nordisk, and Merck

• Ginkgo’s Cell Engineering segment generated services revenue, which does not include downstream value share revenue, of $44 million, a 72% increase versus the second quarter of 2022

• Ginkgo’s Biosecurity segment generated $35 million of revenue in the second quarter. As the COVID-19 public health emergency came to an end in the United States during the quarter, Biosecurity revenue continues to shift away from COVID-19 testing programs in schools and communities towards a more recurring model focused on long-term biosecurity infrastructure

o Concentric continues to expand internationally, with partnerships in 10 countries outside the U.S., including a recently announced Memorandum of Understanding in Panama, our first partnership in Latin America and a key international hub

• Across both segments, Ginkgo continues to advance its relationships with the US government and has been recently awarded contracts from the Intelligence Advanced Research Projects Agency (IARPA) and the Defense Advanced Research Projects Agency (DARPA) to develop improvements in biosecurity and biomanufacturing, in addition to ongoing biosecurity work with the US Centers for Disease Control and Prevention (CDC)

Appointment of Shyam Sankar as Chair of Ginkgo’s Board of Directors

Shyam Sankar, who has served on Ginkgo’s board of directors since 2015, has been unanimously appointed Chair of Ginkgo’s board. Mr. Sankar is the Chief Technology Officer at Palantir Technologies and brings a wealth of experience in key technology and growth areas for Ginkgo, including artificial intelligence and government partnerships. Marijn Dekkers, who has served as Ginkgo’s Chair since joining the board in 2019, will remain an active director on the board.

“We are so excited to have Shyam step into this leadership position on our board as we see real opportunities in areas in which he’s a world expert, including artificial intelligence,” said Jason Kelly, co-founder and CEO of Ginkgo. “Shyam has been extremely helpful over the last eight years of tremendous growth, and we look forward to his guidance and leadership as he steps into this new role. Shyam is building on the strong foundation Marijn has built. I’m extremely grateful for Marijn’s leadership and partnership throughout his tenure as Chair and look forward to continued collaboration as he continues in a director role. We look forward to working with both Shyam and Marijn in Ginkgo’s next phase of growth.”

Second Quarter 2023 Financial Highlights

• Second quarter 2023 Total revenue of $81 million, down from $145 million in the comparable prior year period, a decrease of 44% primarily driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity segment

• Second quarter 2023 Cell Engineering revenue of $45 million, up from $44 million in the comparable prior year period

o Cell Engineering services revenue, which does not include downstream value share revenue, increased by 72% in the second quarter of 2023 compared to the prior year period

• Second quar